At a glance

ClinicalIndex Comparison Record

N/ACompleted· 20 enrolled

Drug / intervention

Memantine +1 moredrug

Likely dose

Memantine 5mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00294554

NCT00294554N/ACompleted

Compare CT.gov

Double-Blind Placebo-Controlled Trial of Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

Johns Hopkins University·interventional·Posted Feb 22, 2006·Updated Sep 12, 2017

In Brief

A clinical study evaluating Memantine and Placebo Oral Tablet for Parkinson's Disease and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this research is to evaluate the usefulness of memantine, compared to placebo (sugar pill), for the treatment of cognitive impairment in patients with idiopathic Parkinson's disease (PD) and dementia. Memantine is used as a safe and effective treatment for patients with Alzheimer's disease. Cognitive impairment includes concentration and memory difficulties. We will look at how well this medication helps your cognitive impairment, how well you tolerate this medication (including its effects on your motor symptoms of PD) your activities of daily living, your emotions, and any medical conditions you might have. We will interview a person you choose as your "informant".

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsParkinson's Disease, Cognitive Impairment, Dementia

CountriesUnited States

CollaboratorsForest Laboratories

Timeline

N/ACompletedFinished

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

First PostedFeb 2006

Enrollment StartApr 2006

Primary CompletionSep 2008

Study CompletionDec 2008

TodayJul 2026

First PostedFeb 22, 2006

Enrollment StartApr 1, 2006

Primary CompletionSep 1, 2008

Study CompletionDec 1, 2008

TodayJul 2, 2026

Enrollment to primary: 2.4 yearsPosted 20.4 years ago

Interventions

Memantinedrug

Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.

Placebo Oral Tabletdrug

Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.